SEATTLE, June 4, 2015 /PRNewswire/ -- Immunexpress, Inc. today announced that Dr. Antony Rapisarda, Director Medical Affairs, will present data at the Pathology Diagnostics Conference on June 11 in San Diego to demonstrate the utility of its SeptiCyte® Lab test to aid in the clinical assessment of sepsis. The presentation will include data from five patient cohorts that are part of the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) Consortium. The MARS Consortium is one of the largest collaborations of academic and industry partners dedicated solely to improving sepsis outcomes.
- Oral presentation: "A Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically Ill Patients"
Session: Multiplex Biomarker Diagnostics and Technology
Presenter: Dr. Antony Rapisarda
Date: Thursday, June 11
Time: 2:45 p.m. PDT
Additional information may be found at https://www.gtcbio.com/conferences/pathology-diagnostics-overview.
Sepsis is a life-threatening condition that arises when the body's response to infection damages its own tissues and organs. Sepsis diagnostics today aim to identify the pathogen only and therefore have serious limitations in respect of speed and sensitivity. The Immunexpress SeptiCyte® solution evaluates the host immune response to aid clinicians in quickly and accurately diagnosing sepsis.
About SeptiCyte® Lab
SeptiCyte® Lab quantifies directly from whole blood specific molecular markers from the patient's own immune system – the "host response." Immunexpress has validated hundreds of nucleic acid and protein expression biomarkers that, in different combinations, answer specific clinical questions about sepsis. Patented biomarkers, algorithms and analysis methods are used to interpret information about the sepsis host response.
Immunexpress is a molecular diagnostic company committed to improving outcomes for patients with, or at risk of, sepsis. Immunexpress's core competency is the clinical validation of genomic and proteomic biomarkers and the translation of these novel biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care (POC) sample-to-answer platforms. Immunexpress is based in Seattle. For more information visit www.Immunexpress.com.
SOURCE Immunexpress, Inc.